UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1221-9
Program Prior Authorization/Notification
Medication Xermelo® (telotristat ethyl)
P&T Approval Date 6/2017, 6/2018, 6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 6/2024. 6/2025
Effective Date 9/1/2025
1. Background:
Xermelo (telotristat ethyl) is a tryptophan hydroxylase inhibitor indicated for the treatment of
carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults
inadequately controlled by SSA therapy.
2. Coverage Criteriaa:
A. Carcinoid Syndrome Diarrhea
1. Initial Authorization
a. Xermelo will be approved based on all of the following criteria:
(1) Diagnosis of carcinoid syndrome diarrhea
-AND-
(2) Diarrhea is inadequately controlled with somatostatin analog therapy (e.g.,
octreotide, Sandostatin LAR, Somatuline Depot, Lanreotide)
-AND-
(3) Used in combination with somatostatin analog therapy (e.g., octreotide, Sandostatin
LAR, Somatuline Depot, Lanreotide)
Authorization will be issued for 12 months.
2. Reauthorization
a. Xermelo will be approved based on the following criterion:
(1) Documentation of positive clinical response to Xermelo
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Xermelo® [package insert]. Deerfield, IL: TerSera Therpeutics LLC; September 2022.
Program Prior Authorization/Notification – Xermelo (telotristat)
Change Control
6/2017 New program.
6/2018 Annual review with no change to criteria.
6/2019 Annual review with no changes to criteria.
6/2020 Annual review with no changes to criteria or reference.
6/2021 Annual review with no changes to criteria.
6/2022 Annual review with no changes to criteria. Updated references.
6/2023 Annual review. Added Lanreotide to SSA examples. Updated reference
and added state mandate footnote.
6/2024 Annual review. Updated initial authorization duration to 12 months.
6/2025 Annual review with no changes to criteria.
© 2025 UnitedHealthcare Services, Inc.
2